Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Rheumatology (Oxford, England)|January 10, 2025
Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticaseOrrin M Troum, Mai Duong, Katie Obermeyer, et al.
Arthritis Research & Therapy|December 27, 2022
Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trialJohn K Botson, Katie Obermeyer, Brian LaMoreaux, et al.
ACR Open Rheumatology|August 14, 2025
Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial AnalysisYael Klionsky, Karina D Torralba, Katie Obermeyer, et al.
Frontiers in Immunology|April 18, 2025
Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trialAbdul Abdellatif, Lin Zhao, Katie Obermeyer, et al.
Therapeutic Advances in Musculoskeletal Disease|March 2, 2026
Plain language summary: gout remission with pegloticaseYael Klionsky, Karina D Torralba, Katie Obermeyer, et al.
Frontiers in Immunology|April 18, 2025
Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trialAbdul Abdellatif, Lin Zhao, Katie Obermeyer, et al.
Rheumatology Advances in Practice|December 16, 2024
Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findingsJohn Botson, Katie Obermeyer, Brian LaMoreaux, et al.
Diabetes Care|June 25, 2010
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemiaHarold E Bays, Eli M Roth, James M McKenney, et al.
ACR Open Rheumatology|January 23, 2025
Pegloticase and Methotrexate Cotherapy in Patients With Uncontrolled Gout With Prior Pegloticase Monotherapy Failure: Findings of an Open-Label TrialOrrin M Troum, John K Botson, Katie Obermeyer, et al.
The Journal of Rheumatology|September 16, 2020
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)John K Botson, John R P Tesser, Ralph Bennett, et al.
Pageof 2